tiprankstipranks
Trending News
More News >
Sectra AB Class B (SE:SECT.B)
:SECT.B
Advertisement

Sectra AB Class B (SECT.B) AI Stock Analysis

Compare
1 Followers

Top Page

SE:SECT.B

Sectra AB Class B

(SECT.B)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 4o)
Rating:64Neutral
Price Target:
kr329.00
▲(6.96% Upside)
Sectra AB Class B's overall stock score is driven by its strong financial performance, which is the most significant factor. However, the high P/E ratio suggests overvaluation, and technical indicators point to potential bearish momentum, which moderates the overall score.

Sectra AB Class B (SECT.B) vs. iShares MSCI Sweden ETF (EWD)

Sectra AB Class B Business Overview & Revenue Model

Company DescriptionSectra AB (publ) provides solutions for medical IT and cybersecurity sectors in Sweden, the United Kingdom, the Netherlands, and rest of Europe. The company operates through Imaging IT Solutions, Secure Communications, and Business Innovation segments. The Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; maintenance services in the form of support and system monitoring; and consulting services related to integration, system design, data migration, and business development. The Secure Communications segment develops and sells products and services for secure voice and data communications, and protection of society's sensitive IT infrastructure; and project-based development, as well as offers security and threat analyses and system monitoring services for control systems in society's critical operations. The Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; and products for medical education and research projects. It serves public and private healthcare providers comprising hospitals, and hospital and private clinic chains; and government agencies, defense departments, energy companies. Sectra AB (publ) was incorporated in 1957 and is headquartered in Linköping, Sweden.
How the Company Makes MoneySectra generates revenue through multiple channels, primarily by selling and licensing its medical imaging software and systems to hospitals and healthcare providers. The company has a subscription-based model for its cloud services, which provides ongoing revenue from its clients. Additionally, Sectra earns income from maintenance and support contracts for its products, ensuring continuous service and updates. The company also benefits from strategic partnerships with healthcare organizations and technology firms, which enhance its market reach and product offerings. Key factors contributing to its earnings include the growing demand for digital healthcare solutions and the increasing need for secure data management in the medical field.

Sectra AB Class B Financial Statement Overview

Summary
Sectra AB Class B exhibits strong financial health with impressive revenue growth and profitability metrics. The balance sheet is solid with low leverage and high equity efficiency. While cash flow generation is improving, further enhancements in cash flow management could bolster financial stability.
Income Statement
85
Very Positive
Sectra AB Class B demonstrates strong revenue growth with a 49.6% increase in the latest year, supported by a high gross profit margin of 88.65%. The net profit margin of 17.39% and EBIT margin of 22.32% indicate solid profitability. However, a slight decline in EBIT from the previous year suggests potential challenges in cost management.
Balance Sheet
80
Positive
The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.046, indicating minimal leverage risk. A high return on equity of 29.39% reflects efficient use of equity to generate profits. The equity ratio of 51.03% suggests a strong capital structure with substantial equity backing.
Cash Flow
78
Positive
Sectra AB Class B shows a healthy free cash flow growth rate of 15.74%, indicating improved cash generation capabilities. The operating cash flow to net income ratio of 0.54 and free cash flow to net income ratio of 0.88 highlight effective cash conversion. However, the lower operating cash flow coverage ratio compared to previous years suggests room for improvement in cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.28B3.24B2.96B2.35B1.95B1.63B
Gross Profit2.92B543.41M557.55M488.91M1.71B1.48B
EBITDA854.94M795.35M615.06M538.55M477.28M429.01M
Net Income585.76M563.37M428.39M374.96M314.79M275.51M
Balance Sheet
Total Assets3.76B3.76B3.21B2.74B2.19B1.65B
Cash, Cash Equivalents and Short-Term Investments1.43B1.34B804.64M945.24M808.77M454.85M
Total Debt96.75M87.46M31.79M82.26M62.62M73.45M
Total Liabilities1.71B1.84B1.64B1.44B1.11B756.33M
Stockholders Equity2.05B1.92B1.57B1.30B1.08B895.62M
Cash Flow
Free Cash Flow999.08M812.37M75.58M347.70M542.55M304.53M
Operating Cash Flow1.10B922.36M326.33M440.49M616.92M372.19M
Investing Cash Flow-102.01M-113.86M-130.74M-212.79M-68.35M-66.82M
Financing Cash Flow-253.84M-251.88M-222.20M-219.29M-198.75M-198.69M

Sectra AB Class B Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price307.60
Price Trends
50DMA
317.27
Negative
100DMA
332.04
Negative
200DMA
298.14
Positive
Market Momentum
MACD
-2.64
Negative
RSI
57.19
Neutral
STOCH
94.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECT.B, the sentiment is Neutral. The current price of 307.6 is above the 20-day moving average (MA) of 303.55, below the 50-day MA of 317.27, and above the 200-day MA of 298.14, indicating a neutral trend. The MACD of -2.64 indicates Negative momentum. The RSI at 57.19 is Neutral, neither overbought nor oversold. The STOCH value of 94.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SECT.B.

Sectra AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
kr4.49B29.7218.65%1.35%3.45%4.22%
kr20.47B46.403.34%0.73%-1.29%
kr6.28B210.071.32%8.39%-85.36%
€60.41B101.8431.78%0.36%5.74%30.96%
kr60.66B29.536.91%2.06%6.74%21.40%
$1.66B-15.03%-21.56%70.41%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SECT.B
Sectra AB Class B
307.60
18.47
6.39%
SE:GETI.B
Getinge
222.90
30.69
15.97%
SE:VITR
Vitrolife AB
150.80
-90.82
-37.59%
SE:BICO
BICO Group AB Class B
22.22
-16.32
-42.35%
SE:CEVI
CellaVision AB
183.40
-60.00
-24.65%
SE:XVIVO
Xvivo Perfusion AB
193.20
-268.80
-58.18%

Sectra AB Class B Corporate Events

Sectra AB Reports Strong Growth and Strategic Transition in Q1 2025/2026
Sep 4, 2025

Sectra AB’s first quarter of 2025/2026 saw significant growth, with order bookings doubling and sales increasing across all operating areas, particularly in the US and Sweden. The company is transitioning to a service-based model, resulting in increased recurring revenue, especially from cloud services. Sectra’s strategic focus on medical IT and cybersecurity, coupled with its new certifications in healthcare cybersecurity, positions it well for future growth, despite short-term financial impacts from its business model transformation.

The most recent analyst rating on ($SE:SECT.B) stock is a Hold with a SEK341.00 price target. To see the full list of analyst forecasts on Sectra AB Class B stock, see the SE:SECT.B Stock Forecast page.

Sectra AB Announces 2025 Annual General Meeting
Aug 5, 2025

Sectra AB has announced its Annual General Meeting (AGM) for shareholders, scheduled for September 9, 2025, in Linköping, Sweden. The meeting will provide an opportunity for shareholders to engage with the company and learn more about its offerings, with options for postal voting available to ensure broad participation.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025